Pharmaceuticals
I-Mab Strengthens Senior Executive Team with New Chief Financial Officer and Chief Strategy Officer Appointments
SHANGHAI and GAITHERSBURG, Md., Nov. 1, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced the appointment ofJohn Long as the Company's Chief Finan...
2021-11-01 20:00
1574
Bionomics Receives FDA Clearance of IND for Evaluation of BNC210 in a Phase 2 Social Anxiety Disorder PREVAIL Study
* U.S. FDA clearance of IND for BNC210 evaluation as an acute treatment for patients with Social Anxiety Disorder in a Phase 2 clinical trial, the PREVAIL Study * The PREVAIL Study remains on target to initiate by end of 2021 and is expected to read out topline data by end of 2022 ADELAIDE, A...
2021-11-01 18:00
2287
Operating Income of Yiling Pharmaceutical in First 3 Quarters Reaches CNY 8.112 Billion, Up 25.81%
SHIJIAZHUANG, China, Oct. 29, 2021 /PRNewswire/ -- Yiling Pharmaceutical released the three-quarter report on the evening ofOctober 28. In the first three quarters, the operating income of the company reachedCNY 8.112 billion, up 25.81% year on year; the net profit attributable to shareholders of...
2021-10-29 17:17
1416
IMPACT Therapeutics Announced ATR Inhibitor IMP9064 IND Clearance by FDA
SHANGHAI, Oct. 29, 2021 /PRNewswire/ -- IMPACT Therapeutics announced that its ATR inhibitor IMP9064 has received the IND clearance from the U.S. Food and Drug Administration (FDA) for the Phase I/II clinical study, which will begin soon in the U.S. This will be the first in human study for the A...
2021-10-29 14:12
1534
Jubilee Biotech has developed JUBIwatch, "Health and Life are now wearable"
SEOUL, South Korea, Oct. 28, 2021 /PRNewswire/ -- Jubilee Biotech, a startup in South Korea, has developed JUBIwatch, a smart watch and medication management platform that uses microneedles to administer exact amounts of medication at set times. "Wearing, setting up, and sending information on m...
2021-10-28 21:00
1140
HanAll Biopharma Reports Third Quarter 2021 Results
* Q3'21 sales of KRW 25.5 billion increased 15% from the same period last year * Q3'21 operating profit of KRW 2.2 billion grew by 120% compared to Q3'20 * Nine months sales of KRW 76.7 billion and operating profit of KRW 9.2 billion rose by 15% and 67% YoY, repectively SEOUL, South Korea, Oct...
2021-10-28 21:00
1572
Mallinckrodt and Terumo Blood and Cell Technologies Announce Positive Recommendations in Australia for Public Funding of UVADEX® (methoxsalen) for ECP Administration with the THERAKOS® CELLEX® Photopheresis System for Chronic Graft Versus Host Disease (cGvHD) in Adults
– In a dual-review process, two independent advisory committees to the Australian Minister for Health recommended reimbursement based on a favorable clinical and cost-effectiveness comparison – DUBLIN and LAKEWOOD, Colo., Oct. 28, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global ...
2021-10-28 05:48
2154
Frontier Biotechnologies' Long-acting Injectable (Aikening(R)), in a Two Drug Regimen, Proves Safe and Effective for Critically Ill Hospitalized AIDS Patients
LONDON, Oct. 27, 2021 /PRNewswire/ -- Frontier Biotechnologies today shared real-world evidence of Albuvirtide (ABT)-based two drug regimen's safety and efficacy for hospitalized AIDS patients at the European AIDS Clinical Society (EACS) Conference. Observations from a single-center, retrospec...
2021-10-27 20:47
1054
Qilian International Holding Group Limited Completes Phase One of Its Expansion of New Organic Fertilizer Production Facility and Puts It into Production
JIUQUAN, China, Oct. 26, 2021 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), aChina-based pharmaceutical and chemical products manufacturer, today announced that the Company has completed phase one of the expansion of its new organic fertilizer produc...
2021-10-26 20:00
1495
I-Mab Announces Strategic Partnership with Sinopharm in Preparation for Launch of its Innovative Assets in China
* I-Mab strategic partnership with Sinopharm will covers all aspects of the go-to-market process, including authorization of more than 300 Sinopharm's subsidiaries as distributors acrossChina. * I-Mab is on track to submit BLA for third line multiple myeloma (MM) treatment by Q4 2021. * The...
2021-10-26 20:00
2157
Samsung Biologics Reports Third Quarter 2021 Financial Results
* Q3'21 revenue of KRW 450.7 billion increased 64% compared to Q3'20. * Q3'21 operating profit of KRW 167.4 billion increased 196% compared to Q3'20. * Stable supply, strong operational excellence and a high utilization rate across all plants. * Active investment on expansion, pre-sales ac...
2021-10-26 15:23
1714
Angel Pharmaceuticals Announces Approval of IND Application in China for ITK Inhibitor CPI-818
JIAXING, China and BURLINGAME, Calif., Oct. 25, 2021 /PRNewswire/ -- Angel Pharmaceuticals Co., Ltd. ("Angel Pharma") today announced that its IND application for CPI-818, a small molecule ITK inhibitor, has been approved by the Center for Drug Evaluation (CDE) to initiate clinical trials in pati...
2021-10-26 07:30
1485
SCN9A Antisense Pain Killer OLP-1002 Moves into Phase 2a Stage
SEOUL, South Korea, Oct. 25, 2021 /PRNewswire/ -- OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced to initiate a Phase 2a trial for SCN9A antisense pain killer OLP-1002 inAustralia. In the Phase 2a trial of a two stage adaptive design ...
2021-10-25 20:30
1608
111, Inc. Announces Strategic Partnership with Chugai Pharma China Co., Ltd. to Accelerate Innovations in Chronic Disease Management
SHANGHAI, Oct. 25, 2021 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced a strategic cooperation agreement with Chugai Phar...
2021-10-25 19:00
1858
I-Mab Expands U.S. Footprint with New R&D Site in San Diego
- I-Mab will strengthen its global R&D presence, with a new world-class R&D and operational site, located in the heart of the rapidly growingSan Diego biotech hub - The new site will complement I-Mab's Global Clinical Development site in Gaithersburg, Maryland to form an integrated I-Mab US R&...
2021-10-22 20:00
1770
2021 Bio-enzyme Application Explorer Summit held in Chengdu
The event focuses on innovation and development of biochemical pharmaceuticals CHENGDU, China, Oct. 22, 2021 /PRNewswire/ -- The biochemical pharmaceutical industry is facing unprecedented opportunities and challenges with the changing economic and policy environment inChina and abroad. On Octobe...
2021-10-22 14:23
1351
Specialised Therapeutics Enters into a New Supply and Distribution Agreement with Incyte to Launch Two New Cancer Therapies, Tafasitamab and Pemigatinib, in Australia, New Zealand and Singapore
SINGAPORE, Oct. 21, 2021 /PRNewswire/ -- Independent pharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) will partner withIncyte Biosciences International Sàrl,the Swiss-based affiliate of Incyte (NASDAQ:INCY), to launch and distribute two new medicines for its haematology and onc...
2021-10-22 09:00
1668
Kintor Pharma Announces PD-L1/TGF-β dual-targeting antibody (GT90008) Approved for Advanced Solid Tumour Clinical Trial in China
SUZHOU, China, Oct. 21 , 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that the clinical trial of PD-L1/TGF-β dual-targeting antibody (GT90008) fo...
2021-10-21 22:33
2313
Luoxin Pharmaceutical signs licensing agreement with Austria-based Marinomed Biotech AG for Budesolv® Budesonide Nasal Spray
SHANGHAI, Oct. 21, 2021 /PRNewswire/ -- Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. (''Shandong Luoxin''), a subsidiary of Luoxin Pharmaceutical Group Stock Co., Ltd. ("Luoxin Pharmaceutical" or "the company") , signed a licensing agreement withAustria-based Marinomed Biotech AG ("Mar...
2021-10-21 15:58
1351
GenFleet Announces First Patient Dosed in Phase Ib/II Trial of TGF-β R1 Inhibitor in Combination with PD-1 Inhibitor in Global Multi-center Research
PERTH, Australia and TAIPEI and SHANGHAI, Oct. 20, 2021 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the first patient with metastatic sigmoid adenocarcinoma has been dosed inPerth, Aus...
2021-10-21 08:05
1850
Week's Top Stories
Most Reposted
Star-Studded Sponsor Line-up Takes Centre Court at the Singapore Tennis Open 2025
[Picked up by 291 media titles]
2025-01-28 10:49
Sephora Unveils Its First Film, "Beauty & Belonging" Celebrating Diversity and Authenticity
[Picked up by 288 media titles]
2025-01-24 08:00
Dahua Technology Joins Hands with WWF to Expand Sustainability Efforts Globally
[Picked up by 270 media titles]
2025-01-24 12:15
HZICC: Linping Manufacturing Goes Global to Promote City Brand
[Picked up by 266 media titles]
2025-01-24 22:59Sushui Tech to Launch New DMFC Products at Smart Energy Week, Tokyo 2025
[Picked up by 259 media titles]
2025-01-28 09:53
Most Read
BRI UMKM EXPO(RT) 2025 Returns: Showcasing Local Products to the World
2025-01-25 15:38
8288
U Power Announces Pricing of $5.0 Million Registered Direct Offering
2025-01-24 22:18
5648
Industrial legacy boosts tourism development in Shenyang
2025-01-24 22:18
4866